Arcus Biosciences RCUS Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's operating lease right-of-use asset amortization?
- Arcus Biosciences (RCUS) reported operating lease right-of-use asset amortization of $2M in Q1 2026.
- How has Arcus Biosciences's operating lease right-of-use asset amortization changed year-over-year?
- Arcus Biosciences's operating lease right-of-use asset amortization decreased by 0.0% year-over-year, from $2M to $2M.
- What is the long-term trend for Arcus Biosciences's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Arcus Biosciences's operating lease right-of-use asset amortization has grown at a 23.6% compound annual growth rate (CAGR), from $3M to $7M.